Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

View:
Post by consultant99 on Aug 16, 2023 12:56pm

Tic Toc

Ever get that feeling that something isn't right? 


Almost 1 year ago we were looking at a possible Q4 2022 BTD and news on the vaccine initiative. What we gotten is three private placements.

Lots of shareholder optimism but despite Fast Track designation and what appears to be outstanding results the only arbitrator that counts, the FDA, has not bestowed BTD on the company's drug treatment.

I have heard of fashionably late but WTF is going on?
More profit taking by the those having invested via PPs?
Somebody knows something?

Management owes shareholders an explaination as to why BTD hasn't been attained. The Q2 Management notes had better start providing shareholders  with more useful information.

Comment by StevenBirch on Aug 16, 2023 1:41pm
Legitimate points I think you should sell.
Comment by consultant99 on Aug 16, 2023 2:42pm
Good advice but unfortunately it came years too late! I only hold warrants in as I wanted the maximum upside based on the August 2022 financials and management notes. The company had demonstrated results that met and exceeded the FDA requirements for BTD as they had reported to shareholders at the start of the Phase 2 trial. Further the company was in the latter stages of the animal testing of ...more  
Comment by BudFoxx2020 on Aug 16, 2023 2:47pm
You should go further back.  2011,2012,2013,2014.  The company promised commercialization of cancer cure and billions in sales imminent any year now.  Lolololololol.  Then you got these groupies pushing this agenda for almost 13 years . 13 years later these same group are still here pushing the same agenda.  They have to be compensated or associated.  Who would be ...more  
Comment by BudFoxx2020 on Aug 16, 2023 2:36pm
Lol.  They have been pushing this cancer cure since 2010.  Fast track, btd, commercialization, etc, etc.  13 years later they are still pushing the same thing.  Lolololoolol.  The only suspense left here is if this blows up, I wonder if we will ever find out who ScienceFirst, gerbel, oilminer, sky, egochant, wild, etc etc are.  This group have been promoting this ...more  
Comment by Oilminerdeluxe on Aug 16, 2023 2:39pm
Have some dignity, clown.
Comment by gonefishing2022 on Aug 16, 2023 10:03pm
It takes about 15 years to bring a Drug to Be approved and they are just on Track 
Comment by N0taP00p on Aug 16, 2023 10:41pm
It's refreshing to see healthy skepticism vs the usual hopium and drivel from the perennial diehards. I  think they won't be able to raise any more money without some clarity on what the heck is really going on.  It's the data that has most of the  investors here hanging on.  While I'm still hoping for a positive BTD surprise (for once), I wouldn't be ...more  
Comment by plantrader on Aug 17, 2023 7:55am
Agreed. In the world of microcaps, expect the unexpected (both negative and positive). At some point the company will have to address the BTD application process and provide some sort of status. It's the right thing to do after claiming they plan to apply in 1Q 2023. We're 5 months past that now. And you're right, having blinders on (whether pro or con) is literally never a good thing.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250